Scarica l'app Stockscreener
156.70
0.77%
1.20
Dopo l'orario di chiusura:
156.70
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$155.50
Aprire:
$156.95
Volume 24 ore:
758.74K
Relative Volume:
0.67
Capitalizzazione di mercato:
$15.76B
Reddito:
$2.86B
Utile/perdita netta:
$478.60M
Rapporto P/E:
33.57
EPS:
4.6676
Flusso di cassa netto:
$748.70M
1 W Prestazione:
-1.09%
1M Prestazione:
+19.45%
6M Prestazione:
+10.48%
1 anno Prestazione:
+31.55%
Intervallo 1D:
$155.44
$158.63
Intervallo di 1 settimana:
$152.54
$159.76
Portata 52W:
$117.59
$162.39
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
156.70 | 15.64B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
(NBIX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Singer Carnie Wilson Finds Strength in Speaking Out on Mental Health Challenges - SELF Magazine
Neurocrine Biosciences(NBIX.US) Director Sells US$37.82 Million in Common Stock - Moomoo
Neurocrine Biosciences (NASDAQ:NBIX) Shows Affordable Growth Potential - ChartMill
Bernstein initiates coverage of Neurocrine Biosciences (NBIX) with outperform recommendation - MSN
Neurocrine Biosciences director Kevin Gorman sells $37.8m in stock By Investing.com - Investing.com South Africa
Neurocrine Biosciences director Kevin Gorman sells $37.8m in stock - Investing.com UK
Director Shalini Sharp converts 1,659 RSUs into NBIX common stock shares - Stock Titan
NBIX (NBIX) director converts 3,318 RSUs into 10,386 common shares - Stock Titan
Neurocrine (NASDAQ: NBIX) director converts 3,318 RSUs to shares - Stock Titan
Director at Neurocrine (NASDAQ: NBIX) converts 3,318 RSUs to stock - Stock Titan
Neurocrine Biosciences (NBIX) director converts 3,318 RSUs into 3,318 shares - Stock Titan
Neurocrine (NBIX) director converts 3,318 RSUs into common shares - Stock Titan
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Johanna Mercier (NBIX) converts 3,318 RSUs into Neurocrine Biosciences stock - Stock Titan
Director at Neurocrine (NASDAQ: NBIX) converts 1,659 RSUs to shares - Stock Titan
Bernstein initiates Neurocrine stock with outperform rating on drug potential - Investing.com
Bernstein initiates Neurocrine stock with outperform rating on drug potential By Investing.com - Investing.com Canada
Neurocrine Biosciences stock (US62886E1082): focus on INGREZZA momentum and growth outlook - AD HOC NEWS
Will New Real-World INGREZZA (valbenazine) Data in Mild TD Change Neurocrine Biosciences' (NBIX) Narrative - Yahoo Finance
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
A Look At Neurocrine Biosciences (NBIX) Valuation As New INGREZZA Real World Data Gains Attention - Yahoo Finance
Neurocrine Biosciences (NBIX) Valuation Check As New INGREZZA Real World Data Draws Fresh Attention - simplywall.st
New CRENESSITY Dosing Algorithms And INGREZZA Data Might Change The Case For Investing In Neurocrine Biosciences (NBIX) - simplywall.st
Morgan Stanley lists Rule 144 sale of NBIX shares (NBIX) - Stock Titan
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals - ChartMill
New data support early use of Ingrezza in mild tardive dyskinesia - The Pharma Letter
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - Sahm
Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal - RTTNews
Neurocrine Biosciences Says Data Show Functional Improvement in Tardive Dyskinesia With Ingrezza Capsules - Moomoo
Richard F. Pops, Neurocrine Biosciences director, sells $2.36m in stock By Investing.com - Investing.com Australia
Richard F. Pops, Neurocrine Biosciences director, sells $2.36m in stock - Investing.com UK
Neurocrine presents real-world data on tardive dyskinesia drug - Investing.com UK
Neurocrine (NBIX) director sells 15,000 shares under 10b5-1 plan - Stock Titan
Neurocrine Biosciences Finalizes $2.9 Billion Acquisition of Soleno Therapeutics - Moomoo
Neurocrine (NBIX) Reveals Positive Data on INGREZZA for Mild Tar - GuruFocus
Neurocrine presents real-world data on tardive dyskinesia drug By Investing.com - Investing.com Australia
Neurocrine presents data on INGREZZA treatment for mild tardive dyskinesia - StreetInsider
Survey: 'mild' movement disorder disrupts life, most improve on INGREZZA - Stock Titan
Neurocrine Biosciences completes $2.9 billion Soleno acquisition - Investing.com UK
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B - Contract Pharma
Neurocrine Biosciences, Inc. completed the acquisition of Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others. - marketscreener.com
Neurocrine Biosciences completes $2.9 billion Soleno acquisition By Investing.com - Investing.com South Africa
Neurocrine Biosciences Acquires Soleno Therapeutics, Adds VYKAT XR for Prader-Willi Syndrome to Rare Disease Portfolio - Minichart
Soleno Therapeutics Announces Acquisition by Neurocrine Biosciences and Corporate Changes – SEC Form 8-K Filing - Minichart
Neurocrine Closes $2.9 Billion Soleno Acquisition to Expand Rare Disease Portfolio - citybiz
Neurocrine Biosciences completes acquisition of Soleno Therapeutics - marketscreener.com
Soleno Therapeutics completes merger with Neurocrine Biosciences, delists from Nasdaq - Investing.com
Neurocrine Biosciences Completes Acquisition Of Soleno Therapeutics - TradingView
Soleno Therapeutics (NASDAQ: SLNO) taken private at $53 per share in cash deal - Stock Titan
Soleno Therapeutics (NASDAQ: SLNO) deregisters S-3 after Neurocrine merger - Stock Titan
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neurocrine Biosciences Inc Azioni (NBIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sharp Shalini | Director |
May 21 '26 |
Option Exercise |
0.00 |
1,659 |
0 |
4,088 |
| RASTETTER WILLIAM H | Director |
May 21 '26 |
Option Exercise |
0.00 |
3,318 |
0 |
43,678 |
| POPS RICHARD F | Director |
May 21 '26 |
Option Exercise |
0.00 |
3,318 |
0 |
37,798 |
| POON CHRISTINE A | Director |
May 21 '26 |
Option Exercise |
0.00 |
3,318 |
0 |
4,753 |
| Norwalk Leslie V | Director |
May 21 '26 |
Option Exercise |
0.00 |
1,659 |
0 |
4,088 |
| MORROW GEORGE J | Director |
May 21 '26 |
Option Exercise |
0.00 |
3,318 |
0 |
10,386 |
| Mercier Johanna | Director |
May 21 '26 |
Option Exercise |
0.00 |
3,318 |
0 |
6,853 |
| LYONS GARY A | Director |
May 21 '26 |
Option Exercise |
0.00 |
1,659 |
0 |
122,141 |
| GORMAN KEVIN CHARLES | Director |
May 19 '26 |
Option Exercise |
43.24 |
205,088 |
8,868,005 |
756,381 |
| GORMAN KEVIN CHARLES | Director |
May 19 '26 |
Sale |
154.33 |
245,088 |
37,824,872 |
511,293 |
4.44%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):